##common.pageHeaderLogo.altText##

Original article

Vol. 155 No. 12 (2025)

Modelling the health and cost implications of expanded access to HIV, HCV and sexually transmitted infection testing in Switzerland

Cite this as:
Swiss Med Wkly. 2025;155:4581
Published
15.12.2025

Summary

 

BACKGROUND: This study was conducted as part of the Swiss National Programme to Stop HIV, Hepatitis B Virus, Hepatitis C Virus and Sexually Transmitted Infections (NAPS), which aims to reduce the spread of sexually transmitted infections in Switzerland. The goal was to identify the most effective and cost-efficient screening strategies to lower the incidence of human immunodeficiency virus (HIV), hepatitis C virus (HCV), syphilis, Neisseria gonorrhoeae and Chlamydia trachomatis by improving access to screening.

METHODS: A Markov model was developed to assess the impact of various screening strategies among key populations over two years, including men who have sex with men (MSM), female sex workers (FSW) and people who inject drugs (PWID). The model further stratifies individuals based on partner number (MSM) and injection-equipment sharing (PWID). Comprehensive cost estimates for screening and treatment were derived from insurance data, literature and expert opinions. The effectiveness of screening interventions was evaluated by measuring reductions in disease incidence and cost savings, comparing the costs of screening to those of acute and chronic care for prevented infections.

RESULTS: Increased screening frequency among key populations led to a reduction in incidence for all five infections studied. The largest effect was seen in people who inject drugs who share injecting equipment, where HCV incidence fell by up to 76% with four annual screens. However, only screening for HIV, HCV and syphilis proved to be cost-saving. Screening for Chlamydia trachomatis and Neisseria gonorrhoeae consistently incurred net costs due to the high screening costs and relatively low treatment costs.

CONCLUSION: Targeted expansion of screening among key populations can reduce the incidence of HIV, HCV and syphilis in Switzerland, with regular screening offering potential cost savings to insurers under specific coverage and treatment scenarios.

References

  1. 1. Federal Office of Public Health. National Programme on HIV and other STIs [Internet]. 2024 [cited 2025 Feb 14]. Available from: https://www.bag.admin.ch/bag/de/home/strategie-und-politik/nationale-gesundheitsstrategien/nationales-programm-hiv-hep-sti-naps.html
  2. 2. Balakrishna S, Salazar-Vizcaya L, Schmidt AJ, Kachalov V, Kusejko K, Thurnheer MC, et al.; Swiss HIV Cohort Study (SHCS). Assessing the drivers of syphilis among men who have sex with men in Switzerland reveals a key impact of screening frequency: A modelling study. PLOS Comput Biol. 2021 Oct;17(10):e1009529. doi: https://doi.org/10.1371/journal.pcbi.1009529
  3. 3. Federal Office of Public Health (FOPH). Voluntary counselling and testing [Internet]. Swiss Confederation; 2024 [cited 2025 Apr 4]. Available from: https://www.bag.admin.ch/bag/en/home/krankheiten/krankheiten-im-ueberblick/sexuell-uebertragbare-infektionen/freiwillige-beratung-und-testung.html
  4. 4. Schmidt AJ, Marcus U. What’s on the rise in Sexually Transmitted Infections? Lancet Reg Health Eur. 2023 Oct;34:100764. doi: https://doi.org/10.1016/j.lanepe.2023.100764
  5. 5. Schmidt AJ, Rasi M, Esson C, Christinet V, Ritzler M, Lung T, et al. The Swiss STAR trial - an evaluation of target groups for sexually transmitted infection screening in the sub-sample of men. Swiss Med Wkly. 2020 Dec;150(5153):w20392. doi: https://doi.org/10.4414/smw.2020.20392
  6. 6. Vernazza PL, Rasi M, Ritzler M, Dost F, Stoffel M, Aebi-Popp K, et al. The Swiss STAR trial - an evaluation of target groups for sexually transmitted infection screening in the sub-sample of women. Swiss Med Wkly. 2020 Dec;150(5153):w20393. doi: https://doi.org/10.4414/smw.2020.20393
  7. 7. AIDS.ch. Leitfaden Safer Sex [Internet]. [cited 2024 Mar 21]. Available from: https://shop.aids.ch/de/A~1911~45/2~110~Shop/Infomaterial/Schutz-vor-HIV-und-STI/Leitfaden-Safer-Sex/deu-fra
  8. 8. Dr. Gay. Testing advice [Internet]. 2024 [cited 2025 Feb 14]. Available from: https://drgay.ch/en/safer-sex/tested-and-vaccinated/testing-advice
  9. 9. Love Life. STI tests: Important for your sexual health [Internet]. 2024 [cited 2025 Feb 14]. Available from: https://lovelife.ch/de/testen
  10. 10. SwissPrepared. SwissPrepared: Pandemic preparedness in Switzerland [Internet]. 2025 [cited 2025 Feb 21]. Available from: https://www.swissprepared.ch/en/
  11. 11. Federal Office of Public Health (FOPH). HIV-Test auf Initiative der Ärztin oder des Arztes (Provider Initiated Counselling and Testing, PICT): Medizinische Empfehlungen (BAG Bulletin 21/15) [Internet]. 2021 [cited 2025 Feb 25]. Available from: https://www.bag.admin.ch/dam/bag/de/dokumente/mt/p-und-p/richtlinien-empfehlungen/pict-hiv-test-auf-initiative-des-arztes.pdf.download.pdf/bu-21-15-pict-hiv.pdf
  12. 12. Weatherburn P, Hickson F, Reid DS, Marcus U, Schmidt AJ. European Men-Who-Have-Sex-With-Men Internet Survey (EMIS-2017): design and methods. Sex Res Soc Policy. 2020;17(4):543–57. doi: https://doi.org/10.1007/s13178-019-00413-0
  13. 13. Swissmedic. Swissmedic - The Swiss Agency for Therapeutic Products [Internet]. 2024 [cited 2025 Feb 14]. Available from: https://www.swissmedic.ch/swissmedic/de/home.html
  14. 14. Spezialitätenliste. Spezialitätenliste (SL) und Geburtsgebrechen-Spezialitätenliste (GGSL) by the BAG/FOPH [Internet]. 2024 [cited 2025 Feb 14]. Available from: https://www.spezialitätenliste.ch
  15. 15. TARMED. Tarifstruktur TARMED by the BAG/FOPH [Internet]. 2018 [cited 2025 Feb 14]. Available from: https://www.bag.admin.ch/bag/de/home/versicherungen/krankenversicherung/krankenversicherung-leistungen-tarife/Aerztliche-Leistungen-in-der-Krankenversicherung/Tarifsystem-Tarmed.html
  16. 16. Swiss Society of Infectious Diseases. SSI guidelines [Internet]. 2024 [cited 2024 May 11]. Available from: https://ssi.guidelines.ch
  17. 17. Wainberg MA, Hull MW, Girard PM, Montaner JS. Achieving the 90-90-90 target: incentives for HIV testing. Lancet Infect Dis. 2016 Nov;16(11):1215–6. doi: https://doi.org/10.1016/S1473-3099(16)30383-8
  18. 18. UNAIDS. 90–90–90: An ambitious treatment target to help end the AIDS epidemic [Internet]. 2014 [cited 2025 Feb 14]. Available from: https://www.unaids.org/sites/default/files/media_asset/90-90-90_en.pdf
  19. 19. Neilan AM, Bulteel AJ, Hosek SG, Foote JH, Freedberg KA, Landovitz RJ, et al. Cost-effectiveness of Frequent HIV Screening Among High-risk Young Men Who Have Sex With Men in the United States. Clin Infect Dis. 2021 Oct;73(7):e1927–35. doi: https://doi.org/10.1093/cid/ciaa1061
  20. 20. Phillips AN, Cambiano V, Miners A, Lampe FC, Rodger A, Nakagawa F, et al. Potential impact on HIV incidence of higher HIV testing rates and earlier antiretroviral therapy initiation in MSM. AIDS. 2015 Sep;29(14):1855–62. doi: https://doi.org/10.1097/QAD.0000000000000767
  21. 21. DiNenno EA, Prejean J, Delaney KP, Bowles K, Martin T, Tailor A, et al. Evaluating the Evidence for More Frequent Than Annual HIV Screening of Gay, Bisexual, and Other Men Who Have Sex With Men in the United States: Results From a Systematic Review and CDC Expert Consultation. Public Health Rep. 2018;133(1):3–21. doi: https://doi.org/10.1177/0033354917738769
  22. 22. Cramp ME, Rosenberg WM, Ryder SD, Blach S, Parkes J. Modelling the impact of improving screening and treatment of chronic hepatitis C virus infection on future hepatocellular carcinoma rates and liver-related mortality. BMC Gastroenterol. 2014 Aug;14(1):137. doi: https://doi.org/10.1186/1471-230X-14-137
  23. 23. Coffin PO, Scott JD, Golden MR, Sullivan SD. Cost-effectiveness and population outcomes of general population screening for hepatitis C. Clin Infect Dis. 2012 May;54(9):1259–71. doi: https://doi.org/10.1093/cid/cis011
  24. 24. Durham DP, Skrip LA, Bruce RD, Vilarinho S, Elbasha EH, Galvani AP, et al. The impact of enhanced screening and treatment on hepatitis C in the United States. Clin Infect Dis. 2016 Feb;62(3):298–304. doi: https://doi.org/10.1093/cid/civ894
  25. 25. Houghton M. Discovery of the hepatitis C virus. Liver Int. 2009 Jan;29(s1 Suppl 1):82–8. doi: https://doi.org/10.1111/j.1478-3231.2008.01925.x
  26. 26. Kusejko K, Salazar-Vizcaya L, Shah C, Stöckle M, Béguelin C, Schmid P, et al.; Swiss HIV Cohort Study. Sustained Effect on Hepatitis C Elimination Among Men Who Have Sex With Men in the Swiss HIV Cohort Study: A Systematic Re-Screening for Hepatitis C RNA Two Years Following a Nation-Wide Elimination Program. Clin Infect Dis. 2022 Nov;75(10):1723–31. doi: https://doi.org/10.1093/cid/ciac273
  27. 27. Tuite AR, Fisman DN, Mishra S. Screen more or screen more often? Using mathematical models to inform syphilis control strategies. BMC Public Health. 2013 Jun;13(1):606. doi: https://doi.org/10.1186/1471-2458-13-606
  28. 28. Chesson HW, Bernstein KT, Gift TL, Marcus JL, Pipkin S, Kent CK. The cost-effectiveness of screening men who have sex with men for rectal chlamydial and gonococcal infection to prevent HIV Infection. Sex Transm Dis. 2013 May;40(5):366–71. doi: https://doi.org/10.1097/OLQ.0b013e318284e544
  29. 29. Tsoumanis A, Hens N, Kenyon CR. Is Screening for Chlamydia and Gonorrhea in Men Who Have Sex With Men Associated With Reduction of the Prevalence of these Infections? A Systematic Review of Observational Studies. Sex Transm Dis. 2018 Sep;45(9):615–22. doi: https://doi.org/10.1097/OLQ.0000000000000824
  30. 30. Vanbaelen T, Rotsaert A, Van Landeghem E, Nöstlinger C, Vuylsteke B, Platteau T, et al. Do pre-exposure prophylaxis (PrEP) users engaging in chemsex experience their participation as problematic and how can they best be supported? Findings from an online survey in Belgium. Sex Health. 2023 Oct;20(5):424–30. doi: https://doi.org/10.1071/SH23037
  31. 31. Hocking JS, Temple-Smith M, Guy R, Donovan B, Braat S, Law M, et al.; ACCEPt Consortium. Population effectiveness of opportunistic chlamydia testing in primary care in Australia: a cluster-randomised controlled trial. Lancet. 2018 Oct;392(10156):1413–22. doi: https://doi.org/10.1016/S0140-6736(18)31816-6
  32. 32. Aids-Hilfe Schweiz. Data on HIV and AIDS [Internet]. 2025 Jul 24 [cited 2025 Feb 14]. Available from: https://aids.ch/en/knowledge/topics/data/
  33. 33. Platt L, Minozzi S, Reed J, Vickerman P, Hagan H, French C, et al. Needle and syringe programmes and opioid substitution therapy for preventing HCV transmission among people who inject drugs: findings from a Cochrane Review and meta-analysis. Addiction. 2018 Mar;113(3):545–63. doi: https://doi.org/10.1111/add.14012
  34. 34. Williams E, Williamson DA, Hocking JS. Frequent screening for asymptomatic chlamydia and gonorrhoea infections in men who have sex with men: time to re-evaluate? Lancet Infect Dis. 2023 Dec;23(12):e558–66. 10.1016/S1473-3099(23)00356-0
  35. 35. Bihl F, Bruggmann P, Castro Batänjer E, Dufour JF, Lavanchy D, Müllhaupt B, et al. HCV disease burden and population segments in Switzerland. Liver Int. 2021;41(12):2803–14. 10.1111/liv.15111
  36. 36. Bruggmann P, Blach S, Deltenre P, Fehr J, Kouyos R, Lavanchy D, et al. Hepatitis C virus dynamics among intravenous drug users suggest that an annual treatment uptake above 10% would eliminate the disease by 2030. Swiss Med Wkly. 2017 Nov;147(4546):w14543. 10.4414/smw.2017.14543
  37. 37. Schmidt AJ, Altpeter E. The Denominator problem: estimating the size of local populations of men-who-have-sex-with-men and rates of HIV and other STIs in Switzerland. Sex Transm Infect. 2019 Jun;95(4):285–91. 10.1136/sextrans-2017-053363
  38. 38. UNAIDS. Switzerland [Internet]. Geneva: UNAIDS; 2021 [cited 2024 Mar 5]. Available from: https://www.unaids.org/en/regionscountries/countries/switzerland
  39. 39. EMIS Project. The European Men-Who-Have-Sex-With-Men Internet Survey [Internet]. 2024 Jul 20 [cited 2025 Feb 14]. Available from: https://www.emis-project.eu
  40. 40. Schmidt AJ, Rasi M, Esson C, Christinet V, Ritzler M, Lung T, et al. The Swiss STAR trial - an evaluation of target groups for sexually transmitted infection screening in the sub-sample of men. Swiss Med Wkly. 2020 Dec;150(5153):w20392. doi: https://doi.org/10.4414/smw.2020.20392
  41. 41. Bigler D, Surial B, Hauser CV, Konrad T, Furrer H, Rauch A, et al. Prevalence of STIs and people’s satisfaction in a general population STI testing site in Bern, Switzerland. Sex Transm Infect. 2023 Jun;99(4):268–71. 10.1136/sextrans-2022-055596
  42. 42. United Nations Office on Drugs and Crime (UNODC). Ending an epidemic: HCV treatment for people who inject drugs (PWID) [Internet]. 2018 [cited 2025 Feb 14]. Available from: https://www.unodc.org/documents/commissions/CND/2019/Contributions/Civil_Society/2018_IAS_Brief_Ending_an_epidemic_HCV_treatment_for_PWID.pdf
  43. 43. Nevin RL, Shuping EE, Frick KD, Gaydos JC, Gaydos CA. Cost and effectiveness of Chlamydia screening among male military recruits: markov modeling of complications averted through notification of prior female partners. Sex Transm Dis. 2008 Aug;35(8):705–13. 10.1097/OLQ.0b013e31816d1f55
  44. 44. Park IU, Tran A, Pereira L, Fakile Y. Sensitivity and specificity of treponemal-specific tests for the diagnosis of syphilis. Clin Infect Dis. 2020 Jun;71 Suppl 1:S13–20. 10.1093/cid/ciaa349
  45. 54. Vetter BN, Ongarello S, Tyshkovskiy A, Alkhazashvili M, Chitadze N, Choun K, et al. Sensitivity and specificity of rapid hepatitis C antibody assays in freshly collected whole blood, plasma and serum samples: A multicentre prospective study. PLoS One. 2020 Dec;15(12):e0243040. 10.1371/journal.pone.0243040
  46. 46. Kohler P, Schmidt AJ, Cavassini M, Furrer H, Calmy A, Battegay M, et al.; Swiss HIV Cohort Study. The HIV care cascade in Switzerland: reaching the UNAIDS/WHO targets for patients diagnosed with HIV. AIDS. 2015 Nov;29(18):2509–15. 10.1097/QAD.0000000000000878
  47. 47. Wandeler G, Dufour JF, Bruggmann P, Rauch A. Hepatitis C: a changing epidemic. Swiss Med Wkly. 2015 Feb;145(506):w14093. 10.4414/smw.2015.14093
  48. 48. Garnett GP, Aral SO, Hoyle DV, Cates W Jr, Anderson RM. The natural history of syphilis. Implications for the transmission dynamics and control of infection. Sex Transm Dis. 1997 Apr;24(4):185–200. 10.1097/00007435-199704000-00002
  49. 49. Garnett GP, Mertz KJ, Finelli L, Levine WC, St Louis ME. The transmission dynamics of gonorrhoea: modelling the reported behaviour of infected patients from Newark, New Jersey. Philos Trans R Soc Lond B Biol Sci. 1999 Apr;354(1384):787–97. 10.1098/rstb.1999.0432 doi: https://doi.org/10.1098/rstb.1999.0431
  50. 50. Paltiel AD, Weinstein MC, Kimmel AD, Seage GR 3rd, Losina E, Zhang H, et al. Expanded screening for HIV in the United States—an analysis of cost-effectiveness. N Engl J Med. 2005 Feb;352(6):586–95. 10.1056/NEJMsa042088
  51. 51. Potterat JJ, Zimmerman-Rogers H, Muth SQ, Rothenberg RB, Green DL, Taylor JE, et al. Chlamydia transmission: concurrency, reproduction number, and the epidemic trajectory. Am J Epidemiol. 1999 Dec;150(12):1331–9. 10.1093/oxfordjournals.aje.a009965
  52. 52. Cui M, Qi H, Zhang T, Wang S, Zhang X, Cao X, et al. Symptomatic HIV infection and in-hospital outcomes for patients with acute myocardial infarction undergoing percutaneous coronary intervention from national inpatient sample. Sci Rep. 2024 Apr;14(1):9832. 10.1038/s41598-024-59920-9
  53. 53. European Centre for Disease Prevention and Control. Chlamydia infection [Internet]. 2024 Aug 5 [cited 2025 Feb 14]. Available from: https://www.ecdc.europa.eu/en/chlamydia-infection
  54. 54. Maheshwari A, Ray S, Thuluvath PJ. Acute hepatitis C. Lancet. 2008 Jul;372(9635):321–32. 10.1016/S0140-6736(08)61116-2
  55. 55. Martín-Sánchez M, Fairley CK, Ong JJ, Maddaford K, Chen MY, Williamson DA, et al. Clinical presentation of asymptomatic and symptomatic women who tested positive for genital gonorrhoea at a sexual health service in Melbourne, Australia. Epidemiol Infect. 2020 Sep;148:e240. 10.1017/S0950268820002265
  56. 56. Grebely J, Matthews S, Causer LM, Feld JJ, Cunningham P, Dore GJ, et al. We have reached single-visit testing, diagnosis, and treatment for hepatitis C infection, now what? Expert Rev Mol Diagn. 2024 Mar;24(3):177–91. 10.1080/14737159.2023.2292645